Home › Myeloproliferatieve neoplasmata › Texas › Houston
Myeloproliferatieve neoplasmata klinische studies in Houston, TX
16 studies voor Myeloproliferatieve neoplasmata zoeken deelnemers op locaties in en rond Houston (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruterenFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
RekruterenFase 1
- The University of Texas, MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruterenObservatieonderzoek
- Texas Children's Hospital, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RekruterenFase 1/2
- MD Anderson, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RekruterenFase 1
- M D Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekruterenFase 2
- The University of Texas MD Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
RekruterenFase 1/2
- M D Anderson Cancer Center, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RekruterenFase 2
- M D Anderson Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
RekruterenObservatieonderzoek
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RekruterenFase 1
- University of Texas M. D. Anderson Cancer Center, Houston
Asciminib Roll-over Study
RekruterenFase 4
- Uni Of TX MD Anderson Cancer Cntr, Houston
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RekruterenFase 2
- M D Anderson Cancer Center, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RekruterenFase 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RekruterenFase 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
RekruterenFase 1
- The University of Texas MD Anderson Cancer Center, Houston
Myeloproliferatieve neoplasmata studies in andere steden
- New York City, NY15 studies
- Boston, MA14 studies
- Milwaukee, WI10 studies
- Miami, FL10 studies
- Durham, NC9 studies
- Baldwin Park, CA9 studies
- Seattle, WA9 studies
- Chicago, IL9 studies
- Portland, OR8 studies
- Cleveland, OH8 studies
- Atlanta, GA8 studies
- Philadelphia, PA8 studies
Andere studies in Houston
- Niet-kleincellige longkanker145 studies
- Borstkanker126 studies
- Kanker (alle vormen)121 studies
- Metastatische kanker104 studies
- Colorectale kanker102 studies
- Eierstokkanker89 studies
- Acute myeloïde leukemie85 studies
- Longkanker78 studies
- Prostaatkanker76 studies
- Endometriumkanker68 studies
- Aldermeesklierkanker61 studies
- Melanoom59 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.